Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 375 results
Press release cover image

Sep 10, 2026

CDT Highlights Sarborg’s Application of Signature Intelligence and Quantum Computing Models to Mental Health

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 10, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today notes the announcement from Sarborg Limited regarding the successful application of its patented Signature Intelligence and quantum computing models to mental health and neuropsychiatric drug discovery. Mental health represents a significant global healthcare opportunity, with more than 1 billion people globally1 living with a mental disorder and depressio
Press release cover image

Sep 9, 2026

Novalix and OpenBench Partner to Create Fee-For-Success Drug Discovery for Life Science Organizations

Strasbourg, France and San Francisco,CA, September 9, 2026.. Novalix and OpenBench areproud to announce a strategic partnership that re-imagines and accelerates drugdiscovery by delivering experimentally validated chemical hit series through afee-for-success model.OpenBench virtually screens trillions ofcompounds, identifying and synthesizing the most promising hits. Thesecandidates are passed on to Novalix where world-class in vitro screeningand characterization surface actionable, meaningful s
A minimalist representation of a small molecule structure in a dark palette.

Sep 8, 2026

Schrödinger births new immunology and inflammation biotech, Tectora Therapeutics

Schrödinger has unveiled Tectora Therapeutics, a new biotech entity focused on immunology and inflammation, backed by a $55 million Series A funding round.Tectora Therapeutics emerges from Schrödinger's strategic initiative to expand its footprint in drug development, particularly in immune diseases. By contributing two early-stage small molecule programs, Schrödinger not only gains an equity position in Tectora but also stands to benefit from potential future milestones and royalties. This coll
Flat illustration of a DNA strand and AI molecule

Sep 5, 2026

Rakovina Therapeutics Shifts 72% of Budget to AI Cancer Programs

Rakovina Therapeutics has significantly increased its allocation to AI-driven drug discovery, now dedicating 72% of its budget to this area as of Q2 2026, up from 57% the previous year. This strategic pivot comes alongside a notable reduction in overall expenses, with the company reporting a 41% decrease in net loss, indicating a more efficient operational model.The company’s focus on AI-supported cancer therapies is evident as it channels resources into three main programs targeting DNA damage
A test tube with a chemical compound in a dimly lit lab setting.

Sep 4, 2026

Rakovina Therapeutics Shifts 72% of Budget to AI Cancer Programs

Rakovina Therapeutics has significantly increased its investment in AI-driven drug discovery, allocating 72% of its budget to this area in Q2 2026, up from 57% the previous year. This strategic shift is particularly noteworthy as the company simultaneously reduced its net loss by 41%, demonstrating a commitment to advancing its three AI-supported cancer programs while managing costs effectively.The reduction in overall expenses, particularly a 63% decrease in general and administrative costs, ha
Press release cover image

Sep 3, 2026

Nuffield Department of Medicine at the University of Oxford and 2U Launch New Program in AI-Driven Drug Discovery

New partnership brings the Nuffield Department of Medicine into 2U's growing portfolio of partnerships with schools and departments across the University of OxfordARLINGTON, Va. and OXFORD, England, Sept. 3, 2026 /PRNewswire/ -- 2U, a global leader in higher education, today announced a new partnership with the Nuffield Department of Medicine (NDM) at the University of Oxford to launch the Oxford AI in Drug Discovery and Medicine Programme, a six-week online executive education program that equi
A minimalist illustration of a DNA strand and molecule representing AI in drug discovery.

Sep 3, 2026

Boehringer signs AI drug discovery deal with Owkin

Boehringer Ingelheim has partnered with Owkin to enhance its drug discovery efforts through the AI platform K Pro, joining other pharmaceutical giants like Sanofi and AstraZeneca in leveraging this innovative technology.K Pro, introduced at the previous ESMO cancer congress, functions as an AI Scientist, enabling researchers to analyze complex medical data using straightforward language rather than intricate coding. This platform assists in uncovering biological patterns, disease characteristics
Press release cover image

Sep 2, 2026

Ono Pharma Enters into a Drug Discovery Partnership with Aitia in Neurological Diseases

— Leveraging Cutting-Edge Causal AI-Based Digital Twins —Aitia’s Gemini Digital Twin (GDT) platform enables the inference of causal relationships to identify novel drug targets, which is not possible with conventional correlation-based AI. Each GDT is a virtual patient model that reflects the disease characteristics of real patients.GDTs are built by Aitia’s causal AI-based REFS™ technology, which is expected to be highly compatible with the discovery of novel therapeutic targets for neurologica
Press release cover image

Sep 1, 2026

DnaK Therapeutics & GATC Health Forge A Partnership To Evaluate, Accelerate & Prioritize Cancer Drug Candidates Using AI Platform

TAMPA, Fla. and IRVINE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- DnaK Therapeutics and GATC Health Corp jointly announced today a collaboration to use GATC’s proprietary artificial intelligence platform to evaluate and prioritize 16 innovative, potential cancer drug candidates. By applying GATC’s predictive AI platform early in the drug-development process, DnaK will be able to prioritize the most promising molecules for preclinical studies, obviating months off traditional experimental time
Press release cover image

Aug 28, 2026

Clicklinks | Sanyou Bio Launches Clicklinks, an AI-Driven Innovation Hub for Original Drug Discovery

SHANGHAI, Aug. 28, 2026 /PRNewswire/ -- Sanyou Biopharmaceuticals Co., Ltd. (hereinafter referred to as "Sanyou Bio"), today announced the official launch of Clicklinks, an AI-STAL and SAI-DA powered collaborative network designed to support original drug discovery and preclinical development.Positioned as an Innovation Hub for Original Drug Discovery, Clicklinks brings together industry partners across the biopharmaceutical value chain to enable more efficient, integrated, and scalable R&D.
Molecular model kit illustrating protein-drug interactions in a lab setting.

Aug 28, 2026

KAIST unveils 'K-Fold,' a sovereign biotech AI model it says is 25 times faster than Google's

KAIST has introduced K-Fold, a groundbreaking biotech AI model that significantly accelerates the prediction of protein-drug binding, positioning itself as a robust alternative to established models like Google DeepMind’s AlphaFold3.Developed by a consortium at KAIST, K-Fold leverages advanced AI technology to predict not only the three-dimensional structures of proteins but also their interactions with drug candidates. This capability is crucial in drug development, enabling faster identificati
Press release cover image

Aug 27, 2026

Ainnocence Shows AINN-P1 Protein Foundation Model Improves Antibody-Antigen Affinity Ranking by 28% - From Sequence Alone

Ainnocence’s foundation model trained from scratch, requiring no structure, no multiple sequence alignment, no fine-tuning, training in hours rather than weeks.Ainnocence Inc.,an AI-driven pharmaceutical & material IP-generating platform company,today released research showing that representations learned by its AINN-P1protein foundation model substantially improve a core task in antibodyengineering: ranking candidate antibody-antigen pairs by binding affinity.Using AINN-P1 as a frozen encod